Immunotherapy in non-small cell lung cancer harbouring driver mutations

Cancer Treat Rev. 2021 May:96:102179. doi: 10.1016/j.ctrv.2021.102179. Epub 2021 Mar 19.

Authors

Alfredo Addeo¹, Antonio Passaro², Umberto Malapelle³, Giuseppe Luigi Banna⁴, Vivek Subbiah⁵, Alex Friedlaender⁶

Affiliations

¹ Oncology Department, University Hospital, Geneva, Switzerland. Electronic address: alfredo.addeo@hcuge.ch.
² Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
³ Department of Haematology/Oncology, Queen Alexandra Hospital, Portsmouth, United Kingdom.
⁴ Department of Public Health, University of Naples Federico II, Naples, Italy.
⁵ Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Oncology Department, University Hospital, Geneva, Switzerland.

PMID: 33798954
DOI: 10.1016/j.ctrv.2021.102179

No abstract available

Publication types

Review

MeSH terms

B7-H1 Antigen / antagonists & inhibitors
B7-H1 Antigen / metabolism
CD8-Positive T-Lymphocytes / drug effects
CD8-Positive T-Lymphocytes / immunology
CTLA-4 Antigen / antagonists & inhibitors
CTLA-4 Antigen / metabolism
Carcinogenesis / genetics
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / immunology
Drug Resistance, Neoplasm / genetics*
Humans
Immune Checkpoint Inhibitors / pharmacology*
Immune Checkpoint Inhibitors / therapeutic use
Immunotherapy / methods*
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / immunology
Lymphocytes, Tumor-Infiltrating / drug effects
Lymphocytes, Tumor-Infiltrating / immunology
Molecular Targeted Therapy / methods
Mutation
Oncogenes / genetics
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / metabolism
Randomized Controlled Trials as Topic
Treatment Outcome
Tumor Microenvironment / drug effects
Tumor Microenvironment / genetics
Tumor Microenvironment / immunology

Substances

B7-H1 Antigen
CD274 protein, human
CTLA-4 Antigen
CTLA4 protein, human
Immune Checkpoint Inhibitors
PDCD1 protein, human
Programmed Cell Death 1 Receptor